Page 133 - 2020年20期

与了人体其他的生理过程，故开发特异性抗血小板药物 [14] GARDINER EE，SHEN Y. Glycoprotein Ⅰb-Ⅸ-Ⅴ[J]. Int
也是非常重要的。与此同时，作用于血小板聚集多个靶 J Biochem Cell Biol，2003，35（8）：1170-1174.
点的药物也可能是未来抗血小板药物研究的方向之一， [15] SCULLY M，CATALAND SR，PEYVANDI F，et al. Ca-
了解血小板激活聚集的机制和相关信号通路可为其研 placizumab treatment for acquired thrombotic thrombocy-
topenic purpura[J]. N Engl J Med，2019，380（4）：335-
究提供切入点。
346.
参考文献
[16] PEYVANDI F，SCULLY M，KREMER HOVINGA JA，
[ 1 ] KOUPENOA M，CLANCY L，CORKERY HA，et al. Cir-
et al. Caplacizumab treatment for acquired thrombotic
culating platelets as mediators of immunity，inflammation，
thrombocytopenic purpura[J]. N Engl J Med，2016，374
and thrombosis[J]. Circ Res，2018. DOI：10.1161/CIR-
（6）：511-522.
CRESAHA.117.310795.
[17] LEI X，REHEMAN A，HOU Y，et al. Anfibatide，a novel
[ 2 ] UNGERER M，MÜNCH G. Novel antiplatelet drugs in
GPⅠb complex antagonist，inhibits platelet adhesion and
clinical development[J]. Thromb Haemost，2013，109（11）：
thrombus formation in vitro and in vivo in murine models
868-875.
of thrombosis[J]. Thromb Haemost，2014，111（2）：279-
[ 3 ] CARRERAS ET，MEGA JL. Dual antiplatelet therapy for
289.
heart disease[J]. Circulation，2014，129（21）：506-508.
[18] DANE K，CHATURVEDI S. Beyond plasma exchange：
[ 4 ] METHAROM P，BERNDT MC，BAKER RI，et al. Cur-
novel therapies for thrombotic thrombocytopenic purpu-
rent state and novel approaches of antiplatelet therapy[J].
ra[J]. Hematology Am Soc Hematol Educ Program，2018.
Arterioscler Thromb Vasc Biol，2015，35（6）：1327-1338. DOI：10.1182/asheducation-2018.1.539.
[ 5 ] RAINGER GE，CHIMEN M，HARRISON MJ，et al. The
[19] XU XR，CARRIM N，NEVES MA，et al. Platelets and
role of platelets in the recruitment of leukocytes during
platelet adhesion molecules：novel mechanisms of throm-
vascular disease[J]. Platelets，2015，26（6）：507-520.
bosis and anti-thrombotic therapies[J]. Thromb J，2016.
[ 6 ] KNOWLES RB，WARNER TD. Anti-platelet drugs and DOI：10.1186/s12959-016-0100-6.
their necessary interaction with endothelial mediators and [20] 李盼，乔建林，徐开林.血小板受体GPⅥ作为抗血栓靶点
platelet cyclic nucleotides for therapeutic efficacy[J].
的研究进展[J].中国实验血液学杂志，2017，25（1）：
Pharmacol Ther，2019. DOI：10.1016/j.pharmthera.2018. 264-269.
08.004. [21] UNGERER M，ROSPORT K，BÜLTMANN A，et al. Nov-
[ 7 ] VARGA-SZABO D，PLEINES I，NIESWANDT B.Cell ad- el antiplatelet drug revacept（dimeric glycoprotein Ⅵ-Fc）
hesion mechanisms in platelets[J]. Arterioscler Thromb specificallcy and efficiently inhibited collagen-induced
Vasc Biol，2008，28（3）：403-412. platelet aggregation without affecting general hemostasis
[ 8 ] TOMAIUOLO M，BRASS LF，STALKER TJ. Regulation in humans[J]. Circulation，2011，123（17）：1891-1899.
of platelet activation and coagulation and its role in vascu- [22] BHATTI M，AYTON S，MICHAIl O，et al. Effect of Bru-
lar injury and arterial thrombosis[J]. Interv Cardiol Clin， ton’s tyrosine kinase inhibitors on platelet aggregation in
2017，6（1）：1-12. patients with acute myocardial infarction[J]. Thromb Res，
[ 9 ] JURK K，KEHREL BE. Platelets：physiology and bio- 2019. DOI：10.1016/j.thromres.2019.04.024.
chemistry[J]. Semin Thromb Hemost，2005，31（4）：381- [23] MANGIN PH，TANG C，BOURDON C，et al. A human-
392. ized glycoprotein Ⅵ（GPⅥ）mouse model to assess the an-
[10] CHEN Y，RUGGERI ZM，DU X. 14-3-3 proteins in plate- tithrombotic efficacies of anti-GPⅥ agents[J]. J Pharma-
let biology and glycoprotein Ⅰb-Ⅸ signaling[J]. Blood， col Exp Ther，2012，341（1）：156-163.
2018，131（22）：2436-2448. [24] SCHULTE V，REUSCH HP，POZGAJOVÁ M，et al.
[11] DA SILVA ML，O’CONNOR MN，KRISTON-VIZI J，et Two-phase antithrombotic protection after anti-glycopro-
al. Type Ⅱ PI4-kinases control Weibel-Palade body bio- tein Ⅵ treatment in mice[J]. Arterioscler Thromb Vasc Bi-
genesis and von Willebrand factor structure in human en- ol，2006，26（7）：1640-1647.
dothelial cells[J]. J Cell Sci，2016，129（10）：2096-2105. [25] INDURUWA I，JUNG SM，WARBURTON EA. Beyond
[12] RIVERA J，LOZANO ML，NAVARRO-NUNEZ L，et al. antiplatelets：the role of glycoprotein Ⅵ in ischemic
Platelet receptors and signaling in the dynamics of throm- stroke[J]. Int J Stroke，2016，11（6）：618-625.
bus formation[J]. Haematologica，2009，94（5）：700-711. [26] 李瀚文，季晖，胡庆华.嘌呤受体P2Y在免疫炎症中的功
[13] CORDINA SM. Novel therapies in the pipeline：directions 能研究进展[J].药学研究，2019，38（4）：218-224.
of research into platelet inhibition[J]. J Vasc Interv Neu- [27] GURBEL PA，JEONG YH，NAVARESE EP，et al. Plate-
rol，2008，1（2）：54-56. let-mediated thrombosis：from bench to bedside[J]. Circ

中国药房 2020年第31卷第20期 China Pharmacy 2020 Vol. 31 No. 20 ·2555 ·